This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmaceuticaldistribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own.
Natalie Bedford, senior vice president, US PharmaceuticalDistribution Services at McKesson, discusses the unique challenges of distributing specialty drugs.
The Italian pharmaceutical company Abiogen Pharma completed an acquisition of a 97.09% stake in the Swiss orphan conditions-focused EffRx Pharmaceuticals on May 29. Altamedics specialises in pharmaceuticaldistribution in hospital settings.
The list includes companies that provide various products and services, including: Manufacturing of reagents for peptide synthesis Large-scale manufacturing of peptides Manufacturing of biologically active peptides and complex organic molecules Scale-up of complex peptides Development and production of therapeutic proteins, such as soluble proteins (..)
Begin the stakeholder mapping process by making a precise list of actors who will play a part in the pharmaceuticaldistribution process. It is therefore important to develop a visual hierarchy of the Key Opinion Leaders of the industry, organized according to their level of authority, influence, and relevance.
It’s important to first identify all actors who will play a part in the pharmaceuticaldistribution process. But what determines which members of the medical community will be valuable to approach for any given proposition? Who are Key Opinion Leaders (KOLs) in the Veterinarian field?
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content